

July 17, 1970

Dr. Allen P. Borger, M.D.  
Dept. Clinical Research  
Pfizer & Co.  
Groton, Connecticut 06340

Dear Allen,

Enclosed is a draft protocol for the *EEG Profile Analysis of Doxepin, III: Comparison of Pamoate and HCl Formulations*, dated 7/15/70.

In reading the initial human data, it seems that the pamoate reduces the rate of absorption, and we are projecting an extension of the duration of each drug experience to 3 hours, rather than the 2 hours we found sufficient for oral doxepin (HCl).

By the time you read this, I will have tried to reach you to ask that we meet on Wednesday afternoon, if possible; or another afternoon later in the week.

My best regards.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

mf/